Pepleomycin-induced pneumonitis resulting in death

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Pepleomycin is an antitumour antibiotic analogous to bleomycin.
• It is used in cancer treatment, often in combination with radiation therapy.

Observation:

• Two cases of fatal pneumonitis are presented following pepleomycin treatment.
• Patients received pepleomycin for epidermoid carcinomas of the head and neck.

Findings:

• Pulmonary changes were observed weeks after pepleomycin cessation in one patient.
• The second patient developed pneumonitis 10 months after treatment initiation.

Implications:

• This highlights the potential for severe pulmonary toxicity with pepleomycin.
• Understanding risk factors is crucial for managing pepleomycin therapy in cancer patients.